Clinical trials: Depression Symptom
Psychological, Depression, Anxiety
The Effects of a Life Coaching Seminar on Gratitude and Psychological Well-Being
This study will consist of a randomized experimental group and a control group, In addition to the control and experimental group, there will also be a non-randomized motivated experimental group.
- Conditions
- Psychological, Depression, Anxiety, Psychological Stress, Mental Health Wellness 1
- Trial name
- NCT04172051
- Testing
- Tony Robbins Date with Destiny
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Depression, Anxiety
Effect of Two Probiotic Formulations on Mental Health and Mood Biomarkers in Adults With Depressive Symptoms
This is a 3-arm, parallel-group, randomized, double-blind, placebo-controlled pilot trial. Sixty adults presenting with depressive symptoms will be randomly allocated to one of 3 groups comprising (1) Bifidobacterium adolescentis…
- Trial name
- NCT05564767
- Testing
- B. adolescentis Bif-038, Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chr Hansen
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction
Trifecta Research Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder…
- Conditions
- PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder
- Trial name
- NCT07717866
- Testing
- Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Axial Therapeutic Research
Major Depressive Disorder (MDD)
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Trial name
- Tarian-1 (NCT07300969)
- Testing
- DT-101
- Where
- 43 sites in United States, Bulgaria and 3 more
- Volunteers
- 300 people
- Sponsor
- Draig Therapeutics Ltd
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Depression
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072929
- Testing
- Armodafinil
- Where
- 40 sites in United States
- Volunteers
- 433 people
- Sponsor
- Cephalon
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Premenstrual Dysphoric Disorder ( PMDD)
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT00824187
- Testing
- EE20/DRSP(YAZ, BAY86-5300)
- Where
- 16 sites in China
- Volunteers
- 187 people
- Sponsor
- Bayer
Fibromyalgia
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily…
- Trial name
- NCT01432236
- Testing
- Pregabalin
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar I Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate several doses of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00094432
- Testing
- Aripiprazole
- Where
- 40 sites in United States
- Volunteers
- 650 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
- Trial name
- NCT01254305
- Testing
- Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Where
- 20 sites in United States
- Volunteers
- 262 people
- Sponsor
- Forest Laboratories
Depression, Depressive Disorder
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of Ganaxolone in Women with Postpartum Depression
- Conditions
- Depression, Depressive Disorder, Depression, Postpartum, Behavioral Symptoms
- Trial name
- NCT03228394
- Testing
- Ganaxolone
- Where
- 16 sites in United States
- Volunteers
- 91 people
- Sponsor
- Marinus Pharmaceuticals
Depression
Bioequivalency Study of Sertraline Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601588
- Testing
- Sertraline
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Depressive Disorder
28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
This study is being conducted to obtain information on the safety and tolerability of repeated doses of GW823296 for 28 days in healthy male and female subjects.
- Trial name
- NCT00511654
- Testing
- GW823296 tablet, Midazolam
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Antidepressant Treatment of AIDS Related Depression.
To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases.
- Trial name
- NCT00000390
- Testing
- Imipramine hydrochloride
- Where
- United States
- Sponsor
- GEIGY Pharmaceuticals
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.